These data suggested that TNFR1 aggravated, whereas TNFR2 alleviated TAC-induced cardiac hypertrophy, dysfunction, and production of pro-inflammatory cytokines. The gene discussed is TNFRSF1B; the disease is persistent truncus arteriosus.